HC Wainwright Issues Pessimistic Estimate for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at HC Wainwright lowered their FY2027 EPS estimates for shares of Denali Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1.68 for the year, down from their prior estimate of $1.69. HC Wainwright currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.53) per share.

DNLI has been the topic of a number of other research reports. Citigroup boosted their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. JPMorgan Chase & Co. dropped their target price on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Wedbush dropped their target price on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, Cantor Fitzgerald downgraded shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Denali Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $38.90.

Denali Therapeutics Stock Up 0.2 %

DNLI stock opened at $29.60 on Friday. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $32.13. The firm has a market cap of $4.24 billion, a P/E ratio of -10.39 and a beta of 1.40. The company’s 50-day moving average price is $27.67 and its two-hundred day moving average price is $23.40.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the business posted ($0.72) EPS.

Insider Activity at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now owns 29,096 shares in the company, valued at $844,656.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by company insiders.

Institutional Trading of Denali Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DNLI. Vanguard Group Inc. lifted its position in Denali Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company’s stock valued at $225,069,000 after acquiring an additional 133,810 shares in the last quarter. Capital Research Global Investors lifted its position in Denali Therapeutics by 107.9% in the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock valued at $124,145,000 after acquiring an additional 3,140,429 shares in the last quarter. Baker BROS. Advisors LP lifted its position in Denali Therapeutics by 43.1% in the 1st quarter. Baker BROS. Advisors LP now owns 3,731,695 shares of the company’s stock valued at $76,574,000 after acquiring an additional 1,124,499 shares in the last quarter. Marshall Wace LLP lifted its position in Denali Therapeutics by 12.7% in the 2nd quarter. Marshall Wace LLP now owns 2,418,833 shares of the company’s stock valued at $56,165,000 after acquiring an additional 272,454 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Denali Therapeutics by 6.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock valued at $32,913,000 after acquiring an additional 84,522 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.